JPWO2020009992A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020009992A5 JPWO2020009992A5 JP2020573342A JP2020573342A JPWO2020009992A5 JP WO2020009992 A5 JPWO2020009992 A5 JP WO2020009992A5 JP 2020573342 A JP2020573342 A JP 2020573342A JP 2020573342 A JP2020573342 A JP 2020573342A JP WO2020009992 A5 JPWO2020009992 A5 JP WO2020009992A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- preparation according
- polypeptide
- dose
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693042P | 2018-07-02 | 2018-07-02 | |
| US62/693,042 | 2018-07-02 | ||
| US201962801014P | 2019-02-04 | 2019-02-04 | |
| US62/801,014 | 2019-02-04 | ||
| PCT/US2019/040129 WO2020009992A1 (en) | 2018-07-02 | 2019-07-01 | Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529777A JP2021529777A (ja) | 2021-11-04 |
| JP2021529777A5 JP2021529777A5 (https=) | 2022-07-08 |
| JPWO2020009992A5 true JPWO2020009992A5 (https=) | 2022-07-08 |
Family
ID=69059780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573342A Pending JP2021529777A (ja) | 2018-07-02 | 2019-07-01 | 進行非小細胞肺癌の治療のための標的ＴＧＦ−β阻害による組み合わせ療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210115145A1 (https=) |
| EP (1) | EP3817740A4 (https=) |
| JP (1) | JP2021529777A (https=) |
| KR (1) | KR20210028219A (https=) |
| CN (1) | CN112638374A (https=) |
| AU (1) | AU2019299318A1 (https=) |
| BR (1) | BR112020026902A2 (https=) |
| CA (1) | CA3105360A1 (https=) |
| IL (1) | IL279862A (https=) |
| MX (1) | MX2021000110A (https=) |
| SG (1) | SG11202013190YA (https=) |
| TW (1) | TW202019405A (https=) |
| WO (1) | WO2020009992A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230365653A1 (en) * | 2020-07-24 | 2023-11-16 | Mabwell (shanghai) Bioscience Co., Ltd. | Tgf-beta rii mutant and fusion protein thereof |
| CN114573701A (zh) * | 2020-12-02 | 2022-06-03 | 上海华奥泰生物药业股份有限公司 | 抗PD-L1/TGF-β双功能抗体及其用途 |
| WO2022171121A1 (zh) * | 2021-02-10 | 2022-08-18 | 同润生物医药(上海)有限公司 | 治疗肿瘤的方法和组合 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130110045A1 (en) * | 2011-10-31 | 2013-05-02 | Ming-Yuan Wu | Single use intravenous therapy administering device with needle safety covers |
| US9676863B2 (en) * | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| CN109640988A (zh) * | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| EP3497130B1 (en) * | 2016-08-12 | 2021-10-27 | Merck Patent GmbH | Combination therapy for cancer |
| WO2018129331A1 (en) * | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
| EP3806842A4 (en) * | 2018-06-13 | 2022-03-16 | Merck Patent GmbH | Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment |
-
2019
- 2019-07-01 SG SG11202013190YA patent/SG11202013190YA/en unknown
- 2019-07-01 WO PCT/US2019/040129 patent/WO2020009992A1/en not_active Ceased
- 2019-07-01 KR KR1020217002888A patent/KR20210028219A/ko not_active Withdrawn
- 2019-07-01 JP JP2020573342A patent/JP2021529777A/ja active Pending
- 2019-07-01 CA CA3105360A patent/CA3105360A1/en active Pending
- 2019-07-01 EP EP19829812.7A patent/EP3817740A4/en not_active Withdrawn
- 2019-07-01 CN CN201980057099.XA patent/CN112638374A/zh active Pending
- 2019-07-01 TW TW108123091A patent/TW202019405A/zh unknown
- 2019-07-01 BR BR112020026902-6A patent/BR112020026902A2/pt not_active Application Discontinuation
- 2019-07-01 AU AU2019299318A patent/AU2019299318A1/en not_active Abandoned
- 2019-07-01 MX MX2021000110A patent/MX2021000110A/es unknown
-
2020
- 2020-12-29 US US17/136,433 patent/US20210115145A1/en not_active Abandoned
- 2020-12-30 IL IL279862A patent/IL279862A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025020147A5 (https=) | ||
| JP2020508317A5 (https=) | ||
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| RU2019106663A (ru) | Комбинированная терапия рака | |
| JP2020514290A5 (https=) | ||
| JP2016520082A5 (https=) | ||
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| JP2019517498A5 (https=) | ||
| JP2021527083A5 (https=) | ||
| JP2021529777A5 (https=) | ||
| JP2018512402A5 (https=) | ||
| JP2021523096A5 (https=) | ||
| JP2022501332A5 (https=) | ||
| JP2021530502A5 (https=) | ||
| Argiris et al. | Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508) | |
| JP2021511344A5 (https=) | ||
| Murphy et al. | State of the art management of metastatic gastroesophageal cancer | |
| JPWO2020009992A5 (https=) | ||
| JPWO2021229235A5 (https=) | ||
| JPWO2019241353A5 (https=) | ||
| JPWO2019222252A5 (https=) | ||
| JPWO2019246595A5 (https=) | ||
| RU2021102112A (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ ПУТЕМ НАПРАВЛЕННОГО ИНГИБИРОВАНИЯ TGFβ ДЛЯ ЛЕЧЕНИЯ ЗАПУЩЕННОГО НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО | |
| TWI814752B (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| RU2020141021A (ru) | Схемы введения доз для направленного ингибирования tgf-в в целях их применения для лечения рака у индивидуумов, ранее не проходивших лечение |